Immutep Pivots Efti Strategy to HNSCC and STS After TACTI-004 Root Cause Analysis
IMMP sits 29% above its 52-week low of $0.293 on elevated volume (11× avg).
Summary
Immutep outlines a focused development strategy for efti in HNSCC (CPS < 1) and neoadjuvant STS, backed by root cause analysis findings pointing to manufacturing-scale differences in TACTI-004.
Key Events · Product Development and Regulatory · IMMP
-
Root Cause Analysis Points to Manufacturing Scale
Structural differences (e.g., subtle N-glycan difference) found between efti manufactured at 200 L and 2,000 L scale; TACTI-004 used only 2,000 L material.
-
New 200 L Manufacturing Run Contracted
Immutep has contracted a new manufacturing run of efti at 200 L scale, the scale used in successful earlier trials (TACTI-mel, TACTI-002, INSIGHT-003).
-
Development Focus Narrowed to Two Indications
Registration-directed development will focus on HNSCC in patients with CPS < 1 and neoadjuvant STS, both with FDA designations (Fast Track and Orphan Drug, respectively).
-
Study Start Targeted for 2H CY2027
Preparations for next clinical trials have commenced, with study start targeted for 2H CY2027, subject to trial design, regulatory interactions, manufacturing timelines, partnering, and resources.
Analysis · IMMP · Life Sciences
A manufacturing-scale difference has been identified as the likely culprit behind TACTI-004's failure, prompting a strategic pivot to two narrower indications where the clinical data is strongest. The company is contracting a new 200 L manufacturing run and targeting study start in 2H CY2027. This is a meaningful strategic reset for a company with a Nasdaq bid price deficiency and an October 2026 deadline to regain compliance.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 30.2% of the 1943 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMMP was trading at $0.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46.4M. The 52-week trading range was $0.29 to $3.53. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.